Literature DB >> 15747421

Elimination of terrestrial rabies in Western European countries.

F Cliquet1, M Aubert.   

Abstract

Since the late 1930s, the red fox (Vulpes vulpes) has been the main vector of rabies in Europe. Practically, decimation of fox population did not prevent the spread of the disease. The only efficient method to control wildlife rabies consisted in using oral vaccination by depositing vaccine baits containing a capsule or a plastic sachet filled with an attenuated anti-rabies liquid vaccine throughout fox habitats. Several live virus vaccines have been and are currently being used: the SAD B19 and SAD P5/88 are rabies strains attenuated in cell culture, the SAG1 and SAG2 strains are apathogenic mutants of an already attenuated rabies strain, and the VRG vaccine is an attenuated vaccinia virus recombinant coding for the rabies glycoprotein gene. These vaccines have different residual pathogenicity. SAG1 and SAG2 are pathogenic only for suckling mice inoculated by intracerebral and oral routes. VRG presents absolutely no rabies risk to humans and the environment and the residual pathogenicity of the vaccinia vector virus is very low even for humans. Other parameters such as the thermostability of the vaccine and the melting point of the bait casing are of utmost importance to guarantee the success of oral vaccination campaigns. Additionally, VRG is the only vaccine that did not interfere with maternal immunity in fox cubs, an important issue for spring campaigns. Successes and failure of national programmes confirm that whatever the ecological conditions, the same rules must be strictly followed to ensure the success of rabies elimination programmes: (i) considering the strategy, any rabies vaccination programme must be organised with the support of a national scientific team specially designated for the task that will have to apply the only methods that have already been proved successful elsewhere in Europe, including rabies surveillance, bait distribution calendar and pattern, and monitoring of this distribution; (ii) vaccination must be pursued for at least two years after the last reported case of rabies in the area; (iii) the choice of a low cost but poorly efficient and poorly stable vaccine does not prove to be cost-beneficial for successful elimination of rabies. Several European countries have become rabies-free: Belgium, Luxembourg, France, Italy, Switzerland, Finland and the Netherlands. Since the European Union is going comprise 25 countries from May 2004, all the scientific knowledge is available for establishing efficient and adapted oral programmes aimed at eliminating terrestrial rabies from this area.

Entities:  

Mesh:

Year:  2004        PMID: 15747421

Source DB:  PubMed          Journal:  Dev Biol (Basel)        ISSN: 1424-6074


  34 in total

1.  Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.

Authors:  Mark R Scheckelhoff; Sam R Telford; Linden T Hu
Journal:  Vaccine       Date:  2005-11-04       Impact factor: 3.641

Review 2.  From bench to almost bedside: the long road to a licensed Ebola virus vaccine.

Authors:  Gary Wong; Emelissa J Mendoza; Francis A Plummer; George F Gao; Gary P Kobinger; Xiangguo Qiu
Journal:  Expert Opin Biol Ther       Date:  2017-11-17       Impact factor: 4.388

3.  One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.

Authors:  Christoph Wirblich; Christopher M Coleman; Drishya Kurup; Tara S Abraham; John G Bernbaum; Peter B Jahrling; Lisa E Hensley; Reed F Johnson; Matthew B Frieman; Matthias J Schnell
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

4.  Live-vaccinia virus encapsulation in pH-sensitive polymer increases safety of a reservoir-targeted Lyme disease vaccine by targeting gastrointestinal release.

Authors:  Aurelie Kern; Chensheng W Zhou; Feng Jia; Qiaobing Xu; Linden T Hu
Journal:  Vaccine       Date:  2016-08-05       Impact factor: 3.641

Review 5.  Developments in rabies vaccines.

Authors:  D J Hicks; A R Fooks; N Johnson
Journal:  Clin Exp Immunol       Date:  2012-09       Impact factor: 4.330

Review 6.  Risk for rabies importation from North Africa.

Authors:  Philippe Gautret; Florence Ribadeau-Dumas; Philippe Parola; Philippe Brouqui; Hervé Bourhy
Journal:  Emerg Infect Dis       Date:  2011-12       Impact factor: 6.883

7.  Novel vaccines to human rabies.

Authors:  Hildegund C J Ertl
Journal:  PLoS Negl Trop Dis       Date:  2009-09-29

Review 8.  Tactics and economics of wildlife oral rabies vaccination, Canada and the United States.

Authors:  Ray T Sterner; Martin I Meltzer; Stephanie A Shwiff; Dennis Slate
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

9.  Large scale dog population demography, dog management and bite risk factors analysis: A crucial step towards rabies control in Cambodia.

Authors:  Véronique Chevalier; Holl Davun; Sopheak Sorn; Pitou Ly; Vutha Pov; Sowath Ly
Journal:  PLoS One       Date:  2021-07-08       Impact factor: 3.240

10.  Recombinant rabies viruses expressing GM-CSF or flagellin are effective vaccines for both intramuscular and oral immunizations.

Authors:  Ming Zhou; Guoqing Zhang; Guiping Ren; Clement W Gnanadurai; Zhenguang Li; Qingqing Chai; Yang Yang; Christina M Leyson; Wenxue Wu; Min Cui; Zhen F Fu
Journal:  PLoS One       Date:  2013-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.